ArticleJournal of clinical microbiology2016
Identification and Antifungal Susceptibility Profiles of Candida haemulonii Species Complex Clinical Isolates from a Multicenter Study in China.
Article in Journal of clinical microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Phylogenetic Profiling of the Diabetic Foot Ulcer Microbiome of an Afro-Caribbean Population.MicrobiologyOpen · 2026Article
- Silent Outbreaks ofAntibiotics (Basel, Switzerland) · 2026Article
- An update on clinically relevant, rare, and emergingClinical microbiology reviews · 2025Review
- Comparative analyses of the biological characteristics, fluconazole resistance, and heat adaptation mechanisms ofApplied and environmental microbiology · 2025Article
- First report of amphotericin B resistantIranian journal of microbiology · 2024Article
- Identification of Virulence Factors in Isolates ofMicroorganisms · 2024Article
- Candida vulturna Outbreak Caused by Cluster of Multidrug-Resistant Strains, China.Emerging infectious diseases · 2023Article
- Whole-genome sequencing of Candida haemulonii species complex from Brazil and the United States: Genetic diversity and antifungal susceptibility.Medical mycology · 2023Article
- Clonal Dissemination of Antifungal-Resistant Candida haemulonii, China.Emerging infectious diseases · 2023Article
- Article
- Review
- Distribution and antifungal susceptibility pattern ofVirulence · 2022Review
- Nationwide Surveillance of Antifungal Resistance ofJournal of fungi (Basel, Switzerland) · 2022Article
- Case report: Catheter related blood stream infection caused byMedical mycology case reports · 2022Article
- The Threat CalledJournal of fungi (Basel, Switzerland) · 2022Article
- Antifungal susceptibility profiles and drug resistance mechanisms of clinicalFrontiers in microbiology · 2022Article
- First two fungemia cases caused byFrontiers in microbiology · 2022Article
- Phenotypic Switching and Filamentation in Candida haemulonii, an Emerging Opportunistic Pathogen of Humans.Microbiology spectrum · 2021Article
- Article
- Amphotericin B and Other Polyenes-Discovery, Clinical Use, Mode of Action and Drug Resistance.Journal of fungi (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida haemulonii complex (Candida haemulonii, Candida haemulonii var. vulnera, and Candida duobushaemulonii) consists of emerging pathogens. Thirty-one isolates from 14 hospitals in China were studied for their species classification and antifungal susceptibilities. Performances of molecular (i.e., ribosomal DNA [rDNA] internal transcribed spacer [ITS] sequencing, D1/D2 sequencing, and ITS sequencer-based capillary gel electrophoresis [SCGE]) and phenotypic identification methods in species identification were compared. Twenty-six (83.9%) of 31 isolates were identified as C. haemulonii and 5 isolates were identified as C. duobushaemulonii by ITS sequencing as the reference method; results obtained by D1/D2 sequencing and ITS SCGE were concordant with those obtained by ITS sequencing for all (100%) of the isolates. All 31 isolates were identified as C. haemulonii by the Vitek matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) system (bioMérieux, France), whereas the Bruker MS system (Bruker Daltoniks, Germany) correctly provided species identification for 77.4% and 100% of isolates using cutoff scores for species of ≥2.0 and ≥1.70, respectively. The Vitek 2 compact (bioMérieux) only identified 9 (29%) of 31 isolates. All isolates showed high MICs for amphotericin B (range, 2 to >8 μg/ml) and fluconazole (≥128 μg/ml) but low MICs (≤0.5 μg/ml) for the echinocandins. Our results reinforce the need for MALDI-TOF MS and/or molecular differentiation of species within the C. haemulonii complex. The multiresistant antifungal susceptibility profile of these isolates represents a challenge to therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.